Immune Thrombocytopenia (ITP) Drug Development

Creative Biolabs is a drug discovery CRO that has many years of experience in the development of drugs for autoimmune diseases. Our diverse drug development platforms include monoclonal antibody development, bispecific antibody development, and cell-based therapy development.

Immune thrombocytopenia (ITP) is one of the best characterized autoimmune diseases. Both antibody-mediated and/or T cell-mediated platelet destruction and impairment of platelet production are key processes. For patients with ITP, the persistently low platelet counts present real and perceived risks for serious and even fatal bleeding events and may therefore require emergency department visits and hospitalization.

Treatment of ITP

First-line treatments focus on the inhibition of autoantibody production and platelet degradation, including corticosteroids with or without intravenous IVIg and anti-D. Second-line therapies consist of splenectomy and/or immunosuppressive drugs such as the B cell-depleting anti-CD20 antibody drug. Thrombopoietin (TPO)-receptor agonists are considered third-line treatments which aim to stimulate platelet production by megakaryocytes.

B cells play a crucial role in both the development and perpetuation of autoimmunity, suggesting that B cell depletion could be a valuable treatment approach for patients with ITP. Therefore, a low-dose anti-CD20 antibody drug, combined with short-term glucocorticoids, provides an effective treatment for ITP to improve long-term outcomes without compromising the safety profile. The use of anti-CD20 antibody drugs could create complete B cell depletion and revert the abnormalities of Treg cells. Additionally, patients with active ITP have a defective T regulatory cell compartment modulated by a B cell-targeted therapy, which is a potential treatment option.

Therapeutic mechanisms of current ITP treatments. Fig.1 Therapeutic mechanisms of current ITP treatments. (Zufferey, 2017)

ITP Drug Development Services

With many years of experience, Creative Biolabs is the premier provider that strives to provide the highest quality autoimmune disease drug development services. Our approach is based on a sequence of procedural building blocks that allow customization of any service request according to your specific needs. You can work with us to select the most appropriate platform, study design, and screening method tailored to each of your drug candidates and research question. Creative Biolabs will advance your preclinical development programs in a time- and cost-effective manner with our comprehensive drug development strategies, which include but not limited to:

  • Monoclonal Antibody Development for ITP
  • Bispecific Antibody Development for ITP
  • Cell-based Therapy for Autoimmune ITP

By partnering with Creative Biolabs, you will gain access to ITP drug development support that increases your research potential to be successful. Please contact us to obtain service excellence and to allow us to become a valuable and trusted partner.

Reference

  1. Zufferey, A.; et al. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). Journal of Clinical Medicine. 2017, 6(2).

For Research Use Only | Not For Clinical Use



Online Inquiry

Autoimmune Diseases

We are dedicated to advancing and facilitating your drug development against autoimmune diseases

Contact us

USA

  • Location:

  • Call:

  • Fax:

  • Email:

UK

  • Location:

  • Call:

  • Email:

Autoimmune Diseases,Drug Development for
Autoimmune Diseases

Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.

Copyright © 2022 Creative Biolabs. All Rights Reserved.